{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T12:32:54Z","timestamp":1770985974519,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T00:00:00Z","timestamp":1576108800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T00:00:00Z","timestamp":1576108800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Eisai Co., Ltd., Japan"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s00520-019-05112-5","type":"journal-article","created":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T15:08:39Z","timestamp":1576163319000},"page":"3819-3829","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Incidence of peripheral neuropathy associated with eribulin mesylate versus vinorelbine in patients with metastatic breast cancer: sub-group analysis of a randomized phase III study"],"prefix":"10.1007","volume":"28","author":[{"given":"Ying","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xichun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,12]]},"reference":[{"issue":"5a","key":"5112_CR1","first-page":"2931","volume":"24","author":"IF Faneyte","year":"2004","unstructured":"Faneyte IF, Kristel PM, van de Vijver MJ (2004) Multidrug resistance associated genes MRP1, MRP2 and MRP3 in primary and anthracycline exposed breast cancer. Anticancer Res 24(5a):2931\u20132939","journal-title":"Anticancer Res"},{"issue":"2 Suppl 2","key":"5112_CR2","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/j.seminoncol.2008.02.010","volume":"35","author":"AJ Chien","year":"2008","unstructured":"Chien AJ, Moasser MM (2008) Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquired. Semin Oncol 35(2 Suppl 2):S1\u2013S14 quiz S39","journal-title":"Semin Oncol"},{"issue":"44","key":"5112_CR3","doi-asserted-by":"crossref","first-page":"75864","DOI":"10.18632\/oncotarget.16439","volume":"8","author":"Q Li","year":"2017","unstructured":"Li Q, Yang Z, Fan J, He J, Zhang B, Yang H, Xie X, Tang Z, Li H, Qiao Y, Zhang P (2017) A nation-wide multicenter 10-year (1999-2008) retrospective study of chemotherapy in Chinese breast cancer patients. Oncotarget 8(44):75864\u201375873","journal-title":"Oncotarget"},{"key":"5112_CR4","unstructured":"Network NCC: NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 4.2018. 2018."},{"key":"5112_CR5","unstructured":"(2011) Eribulin mesylate (Halaven) for breast cancer. Med Lett Drugs Ther 53(1362):30\u201331"},{"issue":"9769","key":"5112_CR6","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","volume":"377","author":"J Cortes","year":"2011","unstructured":"Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Dieras V, Delozier T et al (2011) Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377(9769):914\u2013923","journal-title":"Lancet"},{"issue":"7","key":"5112_CR7","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1200\/JCO.1993.11.7.1245","volume":"11","author":"P Fumoleau","year":"1993","unstructured":"Fumoleau P, Delgado FM, Delozier T, Monnier A, Gil Delgado MA, Kerbrat P, Garcia-Giralt E, Keiling R, Namer M, Closon MT et al (1993) Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 11(7):1245\u20131252","journal-title":"J Clin Oncol"},{"issue":"9","key":"5112_CR8","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/oxfordjournals.annonc.a059019","volume":"5","author":"J Garcia-Conde","year":"1994","unstructured":"Garcia-Conde J, Lluch A, Martin M, Casado A, Gervasio H, De Oliveira C, De Pablo JL, Gorostiaga J, Giron GC, Cervantes A et al (1994) Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapy. Ann Oncol 5(9):854\u2013857","journal-title":"Ann Oncol"},{"issue":"2","key":"5112_CR9","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1200\/JCO.1994.12.2.336","volume":"12","author":"A Romero","year":"1994","unstructured":"Romero A, Rabinovich MG, Vallejo CT, Perez JE, Rodriguez R, Cuevas MA, Machiavelli M, Lacava JA, Langhi M, Romero Acuna L et al (1994) Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. J Clin Oncol 12(2):336\u2013341","journal-title":"J Clin Oncol"},{"issue":"6","key":"5112_CR10","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/ana.24951","volume":"81","author":"A Grisold","year":"2017","unstructured":"Staff NP, Grisold A, Grisold W, Windebank AJ (2017) Chemotherapy-induced peripheral neuropathy: a current review. Ann Neurol 81(6):772\u2013781","journal-title":"Ann Neurol"},{"key":"5112_CR11","doi-asserted-by":"crossref","unstructured":"Addington J, Freimer M: Chemotherapy-induced peripheral neuropathy: an update on the current understanding. F1000Res 2016, 5.","DOI":"10.12688\/f1000research.8053.1"},{"issue":"3","key":"5112_CR12","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ana.410350310","volume":"35","author":"V Chaudhry","year":"1994","unstructured":"Chaudhry V, Rowinsky EK, Sartorius SE, Donehower RC, Cornblath DR (1994) Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol 35(3):304\u2013311","journal-title":"Ann Neurol"},{"issue":"12","key":"5112_CR13","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1007\/s00520-010-1043-2","volume":"19","author":"AL Kautio","year":"2011","unstructured":"Kautio AL, Haanpaa M, Kautiainen H, Kalso E, Saarto T (2011) Burden of chemotherapy-induced neuropathy--a cross-sectional study. Support Care Cancer 19(12):1991\u20131996","journal-title":"Support Care Cancer"},{"issue":"3","key":"5112_CR14","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/clpt.2011.115","volume":"90","author":"DR Pachman","year":"2011","unstructured":"Pachman DR, Barton DL, Watson JC, Loprinzi CL (2011) Chemotherapy-induced peripheral neuropathy: prevention and treatment. Clin Pharmacol Ther 90(3):377\u2013387","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"5112_CR15","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1007\/s00520-011-1365-8","volume":"20","author":"RM Speck","year":"2012","unstructured":"Speck RM, DeMichele A, Farrar JT, Hennessy S, Mao JJ, Stineman MG, Barg FK (2012) Scope of symptoms and self-management strategies for chemotherapy-induced peripheral neuropathy in breast cancer patients. Support Care Cancer 20(10):2433\u20132439","journal-title":"Support Care Cancer"},{"issue":"16","key":"5112_CR16","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.1158\/0008-5472.CAN-04-1169","volume":"64","author":"G Kuznetsov","year":"2004","unstructured":"Kuznetsov G, Towle MJ, Cheng H, Kawamura T, TenDyke K, Liu D, Kishi Y, Yu MJ, Littlefield BA (2004) Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res 64(16):5760\u20135766","journal-title":"Cancer Res"},{"issue":"5","key":"5112_CR17","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1093\/annonc\/mdr380","volume":"23","author":"JS de Bono","year":"2012","unstructured":"de Bono JS, Molife LR, Sonpavde G, Maroto JP, Calvo E, Cartwright TH, Loesch DM, Feit K, Das A, Zang EA, Wanders J, Agoulnik S, Petrylak DP (2012) Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy. Ann Oncol 23(5):1241\u20131249","journal-title":"Ann Oncol"},{"issue":"3","key":"5112_CR18","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2174\/157488611797579302","volume":"6","author":"G Galano","year":"2011","unstructured":"Galano G, Caputo M, Tecce MF, Capasso A (2011) Efficacy and tolerability of vinorelbine in the cancer therapy. Curr Drug Saf 6(3):185\u2013193","journal-title":"Curr Drug Saf"},{"issue":"6","key":"5112_CR19","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1200\/JCO.2013.52.4892","volume":"33","author":"PA Kaufman","year":"2015","unstructured":"Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Velikova G, Olivo MS, He Y, Dutcus CE, Cortes J (2015) Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 33(6):594\u2013601","journal-title":"J Clin Oncol"},{"issue":"3","key":"5112_CR20","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S1470-2045(07)70041-4","volume":"8","author":"M Martin","year":"2007","unstructured":"Martin M, Ruiz A, Munoz M, Balil A, Garcia-Mata J, Calvo L, Carrasco E, Mahillo E, Casado A, Garcia-Saenz JA et al (2007) Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol 8(3):219\u2013225","journal-title":"Lancet Oncol"},{"key":"5112_CR21","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2019.02.002","volume":"112","author":"P Yuan","year":"2019","unstructured":"Yuan P, Hu X, Sun T, Li W, Zhang Q, Cui S, Cheng Y, Ouyang Q, Wang X, Chen Z, Hiraiwa M, Saito K, Funasaka S, Xu B (2019) Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: a randomised clinical trial. Eur J Cancer 112:57\u201365","journal-title":"Eur J Cancer"},{"issue":"1","key":"5112_CR22","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","volume":"47","author":"MS Aapro","year":"2011","unstructured":"Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C, European Organisation for Research and Treatment of Cancer (2011) 2010 Update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47(1):8\u201332","journal-title":"Eur J Cancer"},{"issue":"2","key":"5112_CR23","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1085-9489.2006.00078.x","volume":"11","author":"G Cavaletti","year":"2006","unstructured":"Cavaletti G, Jann S, Pace A, Plasmati R, Siciliano G, Briani C, Cocito D, Padua L, Ghiglione E, Manicone M et al (2006) Multi-center assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity. J Peripher Nerv Syst 11(2):135\u2013141","journal-title":"J Peripher Nerv Syst"},{"issue":"1","key":"5112_CR24","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1046\/j.1526-4637.2001.002001008.x","volume":"2","author":"RC Polomano","year":"2001","unstructured":"Polomano RC, Bennett GJ (2001) Chemotherapy-evoked painful peripheral neuropathy. Pain Med 2(1):8\u201314","journal-title":"Pain Med"},{"issue":"1","key":"5112_CR25","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.seminoncol.2005.12.010","volume":"33","author":"FH Hausheer","year":"2006","unstructured":"Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F (2006) Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol 33(1):15\u201349","journal-title":"Semin Oncol"},{"issue":"4","key":"5112_CR26","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ctrv.2008.01.003","volume":"34","author":"AA Argyriou","year":"2008","unstructured":"Argyriou AA, Polychronopoulos P, Iconomou G, Chroni E, Kalofonos HP (2008) A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat Rev 34(4):368\u2013377","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"5112_CR27","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.soncn.2007.05.001","volume":"23","author":"G Wilkes","year":"2007","unstructured":"Wilkes G (2007) Peripheral neuropathy related to chemotherapy. Semin Oncol Nurs 23(3):162\u2013173","journal-title":"Semin Oncol Nurs"},{"issue":"2","key":"5112_CR28","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00401-009-0586-0","volume":"119","author":"OA Shemesh","year":"2010","unstructured":"Shemesh OA, Spira ME (2010) Paclitaxel induces axonal microtubules polar reconfiguration and impaired organelle transport: implications for the pathogenesis of paclitaxel-induced polyneuropathy. Acta Neuropathol 119(2):235\u2013248","journal-title":"Acta Neuropathol"},{"issue":"11","key":"5112_CR29","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1158\/0008-5472.CAN-10-4184","volume":"71","author":"KM Wozniak","year":"2011","unstructured":"Wozniak KM, Nomoto K, Lapidus RG, Wu Y, Carozzi V, Cavaletti G, Hayakawa K, Hosokawa S, Towle MJ, Littlefield BA et al (2011) Comparison of neuropathy-inducing effects of eribulin mesylate, paclitaxel, and ixabepilone in mice. Cancer Res 71(11):3952\u20133962","journal-title":"Cancer Res"},{"issue":"2","key":"5112_CR30","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s10549-016-3808-x","volume":"157","author":"K Inoue","year":"2016","unstructured":"Inoue K, Saito T, Okubo K, Kimizuka K, Yamada H, Sakurai T, Ishizuna K, Hata S, Kai T, Kurosumi M (2016) Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance. Breast Cancer Res Treat 157(2):295\u2013305","journal-title":"Breast Cancer Res Treat"},{"issue":"24","key":"5112_CR31","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.2146\/ajhp140773","volume":"72","author":"S Goodin","year":"2015","unstructured":"Goodin S, Barbour S, Song J, Berrak E, Cox D (2015) Safety and tolerability of eribulin mesylate in patients with pretreated metastatic breast cancer. Am J Health Syst Pharm 72(24):2150\u20132156","journal-title":"Am J Health Syst Pharm"},{"key":"5112_CR32","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ejca.2016.03.010","volume":"60","author":"P Aftimos","year":"2016","unstructured":"Aftimos P, Polastro L, Ameye L, Jungels C, Vakili J, Paesmans M, van den Eerenbeemt J, Buttice A, Gombos A, de Valeriola D et al (2016) Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial. Eur J Cancer 60:117\u2013124","journal-title":"Eur J Cancer"},{"issue":"3","key":"5112_CR33","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1177\/1078155214525369","volume":"21","author":"G Dranitsaris","year":"2015","unstructured":"Dranitsaris G, Beegle N, Kalberer T, Blau S, Cox D, Faria C (2015) A comparison of toxicity and health care resource use between eribulin, capecitabine, gemcitabine, and vinorelbine in patients with metastatic breast cancer treated in a community oncology setting. J Oncol Pharm Pract 21(3):170\u2013177","journal-title":"J Oncol Pharm Pract"},{"issue":"11","key":"5112_CR34","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1158\/1078-0432.CCR-14-3252","volume":"21","author":"NF Dybdal-Hargreaves","year":"2015","unstructured":"Dybdal-Hargreaves NF, Risinger AL, Mooberry SL (2015) Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent. Clin Cancer Res 21(11):2445\u20132452","journal-title":"Clin Cancer Res"},{"issue":"7","key":"5112_CR35","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1158\/1535-7163.MCT-04-0345","volume":"4","author":"MA Jordan","year":"2005","unstructured":"Jordan MA, Kamath K, Manna T, Okouneva T, Miller HP, Davis C, Littlefield BA, Wilson L (2005) The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 4(7):1086\u20131095","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"5112_CR36","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/med.20242","volume":"31","author":"RA Stanton","year":"2011","unstructured":"Stanton RA, Gernert KM, Nettles JH, Aneja R (2011) Drugs that target dynamic microtubules: a new molecular perspective. Med Res Rev 31(3):443\u2013481","journal-title":"Med Res Rev"},{"issue":"2","key":"5112_CR37","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1212\/01.WNL.0000043691.53710.53","volume":"60","author":"V Chaudhry","year":"2003","unstructured":"Chaudhry V, Chaudhry M, Crawford TO, Simmons-O\u2019Brien E, Griffin JW (2003) Toxic neuropathy in patients with pre-existing neuropathy. Neurology 60(2):337\u2013340","journal-title":"Neurology"},{"issue":"1","key":"5112_CR38","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1212\/WNL.46.1.104","volume":"46","author":"PH Hilkens","year":"1996","unstructured":"Hilkens PH, Verweij J, Stoter G, Vecht CJ, van Putten WL, van den Bent MJ (1996) Peripheral neurotoxicity induced by docetaxel. Neurology 46(1):104\u2013108","journal-title":"Neurology"},{"issue":"4","key":"5112_CR39","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/00043426-200304000-00010","volume":"25","author":"AR Chauvenet","year":"2003","unstructured":"Chauvenet AR, Shashi V, Selsky C, Morgan E, Kurtzberg J, Bell B (2003) Pediatric Oncology Group S: Vincristine-induced neuropathy as the initial presentation of Charcot-Marie-Tooth disease in acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Pediatr Hematol Oncol 25(4):316\u2013320","journal-title":"J Pediatr Hematol Oncol"},{"issue":"3","key":"5112_CR40","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1517\/14740338.2011.543417","volume":"10","author":"D Balayssac","year":"2011","unstructured":"Balayssac D, Ferrier J, Descoeur J, Ling B, Pezet D, Eschalier A, Authier N (2011) Chemotherapy-induced peripheral neuropathies: from clinical relevance to preclinical evidence. Expert Opin Drug Saf 10(3):407\u2013417","journal-title":"Expert Opin Drug Saf"},{"issue":"7","key":"5112_CR41","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1002\/(SICI)1097-0142(19960401)77:7<1356::AID-CNCR20>3.0.CO;2-#","volume":"77","author":"WD Graf","year":"1996","unstructured":"Graf WD, Chance PF, Lensch MW, Eng LJ, Lipe HP, Bird TD (1996) Severe vincristine neuropathy in Charcot-Marie-Tooth disease type 1A. Cancer 77(7):1356\u20131362","journal-title":"Cancer"},{"issue":"2","key":"5112_CR42","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s10549-013-2574-2","volume":"140","author":"LT Vahdat","year":"2013","unstructured":"Vahdat LT, Garcia AA, Vogel C, Pellegrino C, Lindquist DL, Iannotti N, Gopalakrishna P, Sparano JA (2013) Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized phase II study comparing the incidence of peripheral neuropathy. Breast Cancer Res Treat 140(2):341\u2013351","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"5112_CR43","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","volume":"155","author":"M Seretny","year":"2014","unstructured":"Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, Colvin LA, Fallon M (2014) Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain 155(12):2461\u20132470","journal-title":"Pain"},{"issue":"4","key":"5112_CR44","doi-asserted-by":"crossref","first-page":"293","DOI":"10.17772\/gp\/61750","volume":"87","author":"D Izycki","year":"2016","unstructured":"Izycki D, Niezgoda A, Kazmierczak M, Nowak-Markwitz E (2016) Chemotherapy-induced peripheral neuropathy - epidemiology and pathogenesis. Ginekol Pol 87(4):293\u2013299","journal-title":"Ginekol Pol"},{"issue":"6","key":"5112_CR45","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00280-012-1976-x","volume":"70","author":"LA Devriese","year":"2012","unstructured":"Devriese LA, Witteveen PO, Marchetti S, Mergui-Roelvink M, Reyderman L, Wanders J, Jenner A, Edwards G, Beijnen JH, Voest EE, Schellens JH (2012) Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment. Cancer Chemother Pharmacol70(6):823\u2013832","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-019-05112-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-019-05112-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-019-05112-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T00:57:29Z","timestamp":1607648249000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-019-05112-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,12]]},"references-count":45,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["5112"],"URL":"https:\/\/doi.org\/10.1007\/s00520-019-05112-5","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,12]]},"assertion":[{"value":"8 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the International Conference on Harmonization Guidelines for Good Clinical Practice, the Declaration of Helsinki, and the institutional review board\/ethics committee at each site.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The sponsor played a role in designing the study, interpreting the data, and reviewing the draft manuscripts.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the institutional ethical committee and the patient signed an informed consent to participate in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}